WebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they expect the company's stock price to reach $25.83 in the next year. This suggests a possible upside of 175.4% from the stock's current price. WebDec 11, 2024 · Dyne Therapeutics will lease 68,187 square feet at 1560 Trapelo Road in Waltham. Dyne Therapeutics. By Catherine Carlock – Real Estate Editor, Boston Business Journal. Dec 11, 2024.

Dyne Therapeutics Announces FDA Clinical Hold on IND

WebSep 13, 2024 · Summary. Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO. The firm is advancing treatments for various muscle diseases. DYN has yet to enter Phase 1 safety trials, so the ... WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … chronic cough wheezing shortness of breath

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024

WebGlassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne Therapeutics company … WebSee what employees say it's like to work at Dyne Therapeutics. Salaries, reviews, and more - all posted by employees working at Dyne Therapeutics. WebJan 18, 2024 · Dyne received a clinical hold letter from the FDA on Friday, January 14, 2024 requesting additional clinical and non-clinical information for DYNE-251. The Company expects to submit to the FDA its ... chronic cough when talking